Skip to Content

Ticlid (ticlopidine) Disease Interactions

There are 5 disease interactions with Ticlid (ticlopidine):

Major

Ticlopidine (applies to Ticlid) bleeding risks

Major Potential Hazard, High plausibility. Applicable conditions: Coagulation Defect, Thrombocytopathy

The use of ticlopidine is contraindicated in patients with hemostatic disorders such as vascular defect or coagulation dysfunction or active pathological bleeding such as peptic ulcer disease or intracranial hemorrhage. Ticlopidine induces an irreversible inhibition of platelet aggregation resulting in a prolongation of bleeding time.

References

  1. Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand JC "Thrombotic thrombocytopenic purpura related to ticlopidine." Lancet 337 (1991): 774-6
  2. "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc, Palo Alto, CA.
  3. Carlson JA, Maesner JE "Fatal neutropenia and thrombocytopenia associated with ticlopidine." Ann Pharmacother 28 (1994): 1236-8
  4. Ellie E, Durrieu C, Besse P, Julien J, Gbipki-Benissan G "Thrombotic thrombocytopenic purpura associated with ticlopidine ." Stroke 23 (1992): 922-3
  5. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D "Thrombotic thrombocytopenic purpura associated with ticlopidine." Ann Intern Med 128 (1998): 541-4
View all 5 references
Major

Ticlopidine (applies to Ticlid) hepatic dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Liver Disease

The use of ticlopidine is contraindicated in patients with severe hepatic impairment. Ticlopidine is extensively metabolized to inactive forms by the liver. Therapy with ticlopidine should be administered cautiously in patients with mild to moderate hepatic impairment and dosage modifications should be considered. Clinical monitoring of hepatic function and bleeding activity is recommended.

References

  1. "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc, Palo Alto, CA.
  2. Picard-Fraire C "Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function." Agents Actions Suppl 15 (1984): 68-75
  3. Cassidy LJ, Schuster BG, Halparin LS "Probable ticlopidine-induced cholestatic hepatitis." Ann Pharmacother 29 (1995): 30-2
  4. Saltiel E, Ward A "Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states." Drugs 34 (1987): 222-62
View all 4 references
Major

Ticlopidine (applies to Ticlid) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Neutropenia, Thrombocytopenia

The use of ticlopidine is contraindicated in patients with hematopoietic disorders such as neutropenia and/or thrombocytopenia or a past history of thrombotic thrombocytopenic purpura (TTP) or aplastic anemia. Ticlopidine can cause life-threatening hematological adverse reactions, including neutropenia/agranulocytosis, TTP and aplastic anemia. Clinical monitoring of hematopoietic function is required for all patients receiving ticlopidine, since severe hematopoietic disorders may develop suddenly, usually within the first 3 weeks to 3 months of therapy. CBCs (including differential and platelet count) should be performed prior to initiation of ticlopidine and every 2 weeks through the first 3 months or as often as necessary.

References

  1. Khelif A, Assouline D, Ffrench M, Chaumentin G, Viala JJ "Ticlopidine and aplastic anaemia." Br J Haematol 83 (1993): 678-9
  2. Garnier G, Taillan B, Pesce A, Chichmanian RM, Dujardin P "Ticlopidine and severe aplastic anaemia." Br J Haematol 81 (1992): 459-60
  3. Farver DK, Hansen LA "Delayed neutropenia with ticlopidine." Ann Pharmacother 28 (1994): 1344-6
  4. Troussard X, Mayo P, Mosquet B, Reman O, Leporrier M "Ticlopidine and severe aplastic anaemia ." Br J Haematol 82 (1992): 779-80
  5. "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc, Palo Alto, CA.
  6. Dunn P "Aplastic anemia with ticlopidine therapy in two Chinese patients." Ann Pharmacother 30 (1996): 547
  7. Mallet L, Mallet J "Ticlopidine and fatal anemia in an elderly woman." Ann Pharmacother 28 (1994): 1169-71
  8. Ono K, Kurohara K, Yoshihara M, Shimamoto Y, Yamaguchi M "Agranulocytosis caused by ticlopidine and its mechanism." Am J Hematol 37 (1991): 239-42
  9. Lesesve JF, Callat MP, Lenormand B, Monconduit M, Noblet C, Moore N, Caron F, Humbert G, Stamatoullas A, Tilly H "Hematological toxicity of ticlopidine." Am J Hematol 47 (1994): 149-50
  10. Muszkat M, Shapira MY, Sviri S, Linton DM, Caraco Y "Ticlopidine-induced thrombotic thrombocytopenic purpura." Pharmacotherapy 18 (1998): 1352-5
  11. Mataix R, Ojeda E, Perez MC, Jimenez S "Ticlopidine and severe aplastic anaemia." Br J Haematol 80 (1992): 125-6
  12. Martinnunez G, Fdezsoria RR, Sanchezgil F, Benitezcano E "Aplastic anaemia and ticlopidine." Br J Haematol 85 (1993): 633
  13. Arribalzaga K, Garciasuarez J, Lopezrubio M, Krsnik I, Calero MA, Delcampo JF "Sustained granulocyte recovery after g-CSF in a patient with ticlopidine-induced severe aplastic anemia." Am J Hematol 50 (1995): 313
View all 13 references
Moderate

Ticlopidine (applies to Ticlid) hyperlipidemia

Moderate Potential Hazard, Low plausibility.

Ticlopidine can induce increases in serum cholesterol and triglycerides. Serum total cholesterol levels have increased 8% to 10% in some patients within 1 month of initiation of ticlopidine therapy and have persisted at those levels. Clinical monitoring of lipid profiles is recommended during ticlopidine therapy in patients at risk for hyperlipidemia-associated adverse events.

References

  1. "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc, Palo Alto, CA.
Moderate

Ticlopidine (applies to Ticlid) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Ticlopidine is primarily eliminated by the kidney, and there is limited experience in patients with renal impairment. Elevated serum concentration of ticlopidine and prolonged half-live have been noted in patients with mild and moderate renal impairment. Prolonged bleeding times have been reported in patients with moderate renal impairment. Therapy with ticlopidine should be administered cautiously in patients with compromised renal function and dosage modifications may be necessary.

References

  1. "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc, Palo Alto, CA.
  2. Shah J, Teitelbaum P, Molony B, Gabuzda T, Massey I "Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects." Br J Clin Pharmacol 32 (1991): 761-4

Ticlid (ticlopidine) drug interactions

There are 205 drug interactions with Ticlid (ticlopidine)

Ticlid (ticlopidine) alcohol/food interactions

There are 2 alcohol/food interactions with Ticlid (ticlopidine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.